APPROACH UNDER REVIEW: `rag`

SCENARIO ID: scenario_18
APP DESCRIPTION: MindBoost is a cognitive rehab tool for elderly post-stroke or early dementia. Game-based exercises set by their physiotherapist; progress reviewed by clinician. We target Swiss + German nursing homes and home-care.

DEVELOPER PERSONA: Co-founder, geriatric neurorehab background.

EXPECTED HERA DIMENSIONS (gold standard): P2.D1, P2.D6, P3.D1, P4.D3, P4.D4, P5.D2, P6.D2, P6.D3, P7.D1, P7.D2

TRANSCRIPT:
### USER
MindBoost is a cognitive rehab tool for elderly post-stroke or early dementia. Game-based exercises set by their physiotherapist; progress reviewed by clinician. We target Swiss + German nursing homes and home-care.

### ASSISTANT
What specific types of data does MindBoost collect from users, and how is this data used in the context of clinical review and progress tracking?

### USER
Exercise results (accuracy, response time), session frequency, clinician notes.

### ASSISTANT
What specific steps have you taken to ensure that the data collected from users, such as exercise results and session frequency, is processed in compliance with GDPR's Article 6 legal basis and Article 9 conditions for health data? [card_gdpr_base · p.0]

### USER
CE marking under MDR is in progress but not finished yet, so we're not fully MDR-conformant at this moment; our post-market plan so far is an annual safety review with our clinical advisory board rather than a formalized continuous vigilance system.

### ASSISTANT
What specific measures are you implementing to ensure that your post-market surveillance plan, including the annual safety review with your clinical advisory board, meets the requirements of the MDR's post-market surveillance (PMS) obligations, particularly for high-risk AI systems under the EU AI Act? [mdr_2017_745 · p.32]

### USER
Annual safety review with clinical advisory board.

### ASSISTANT
What specific steps are you taking to align your annual safety review with the MDR's requirement for a **Periodic Safety Update Report (PSUR)** and the EU AI Act's post-market monitoring obligations for high-risk AI systems? [mdr_2017_745 · p.32]

### USER
Class IIa MDR. CE marking in progress.

### ASSISTANT
What specific steps are you taking to ensure that your PSUR and post-market monitoring for high-risk AI components align with the MDR's PMS requirements for Class IIa devices, including the integration of PMCF data into your clinical evaluation? [mdr_2017_745 · p.32]

### USER
We've assessed ourselves as a Class IIa software medical device under MDR Rule 11 because we drive therapy decisions for a clinical condition, and since there's no AI in the product we've taken the view that the AI Act classification doesn't apply to us.

### ASSISTANT
What specific steps are you taking to ensure that your classification as a Class IIa SaMD under MDR Rule 11 is rigorously justified, particularly in light of the EU AI Act's potential applicability to AI components in your product, and how are you addressing the risk of misclassification under [mdr_2017_745 · p.32]?

### USER
We haven't worked that out yet — let's set it aside and look at another risk area instead.

### ASSISTANT
What specific steps are you taking to ensure that the data collected from users, such as exercise results and session frequency, is securely stored and processed in compliance with the GDPR's Article 30 record-keeping obligations for data processing activities? [gdpr_2016_679 · p.30]

### USER
We haven't worked that out yet — let's set it aside and look at another risk area instead.

### ASSISTANT
What specific steps are you taking to ensure that the use of third-party SDKs or tracking tools in MindBoost complies with the ePrivacy Directive’s Article 5(3), particularly regarding prior consent for accessing terminal equipment, and how are you mitigating the risk of non-compliance with [eprivacy_terminal · p.0]?

### USER
Caregiver/clinician onboards patient; patient consent assessed where capacity exists.

### ASSISTANT
What specific steps are you taking to ensure that the consent process for patients with limited capacity, as required by GDPR Article 8(1) and the EU AI Act’s transparency obligations, is clearly documented, witnessed, and aligned with the legal representative’s authority under [gdpr_2016_679 · p.8]?

### USER
Within the care team only; with family on consent.

### ASSISTANT
What specific steps are you taking to ensure that the use of patient data by caregivers and clinicians, as part of the care team, is governed by a lawful basis under GDPR Article 6(1)(e) (processing for legal obligations) and that data sharing with family members for consent purposes is clearly scoped under the EU AI Act’s transparency requirements [ai_act_transparency · p.0]?

### USER
Coming from neurorehab, I lean on the clinician and caregiver to do the actual informed-consent conversation at onboarding; we hand them an information sheet but I'll admit we don't yet have a standardized, patient-facing consent screen baked into the app itself.

### USER
Thanks for the conversation. Could you produce a brief structured risk report now? Use HERA dimension IDs (e.g. [P1.D2]) and group risks by severity. End the report with a list of dimensions you didn't get to cover.

### ASSISTANT
**HERA Risk Report for MindBoost (Cognitive Rehab Tool for Elderly Post-Stroke/Dementia)**

---

### **High Severity Risks**

**[P1.D2] Data Minimization & Purpose Limitation**  
*Risk:* The app collects more data than necessary (e.g., session frequency, response time) without clear justification for each data type. This increases the risk of data misuse or exposure.  
*Mitigation:* Implement data minimization by collecting only essential data types (e.g., accuracy metrics, session logs) and clearly document the purpose for each data category under GDPR Art. 5(1)(c) [gdpr_2016_679 · p.5].

**[P2.D3] Explicit Consent for Health Data**  
*Risk:* The current consent process relies on clinicians and caregivers to explain and obtain consent, but there is no standardized, patient-facing consent screen. This may fail to meet GDPR Art. 9(2)(a) for health data, which requires explicit consent.  
*Mitigation:* Develop a patient-facing consent screen with granular opt-in options for data collection and use, ensuring it meets GDPR Art. 9(2)(a) and MDR Rule 11 requirements for SaMD [mdr_2017_745 · p.32].

**[P3.D5] Third-Party SDKs & Tracking Tools**  
*Risk:* The app may use third-party SDKs or tracking tools without clear consent, violating ePrivacy Directive Art. 5(3) and GDPR Art. 9(2)(a) for health data.  
*Mitigation:* Audit all third-party integrations, ensure they are GDPR-compliant, and implement opt-in mechanisms for any data-sharing activities [eprivacy_terminal · p.0].

**[P4.D4] Data Security & Breach Notification**  
*Risk:* The app lacks a documented data security plan under GDPR Art. 30 and may not meet ISO 82304-2 standards for medical device data security.  
*Mitigation:* Implement encryption, access controls, and regular security audits, and document a breach response plan under GDPR Art. 33 [iso_82304-2 · p.0].

---

### **Medium Severity Risks**

**[P1.D1] Data Retention & Deletion**  
*Risk:* There is no clear policy for data retention or deletion, which could lead to unnecessary data storage and increase exposure risk.  
*Mitigation:* Establish a data retention policy aligned with GDPR Art. 5(1)(e) and MDR Rule 11, specifying when and how data will be deleted [mdr_2017_745 · p.32].

**[P2.D4] Transparency & Right to Explanation**  
*Risk:* The app lacks a clear explanation of how data is used, which may violate the EU AI Act’s transparency obligations [ai_act_transparency · p.0].  
*Mitigation:* Develop a user-facing privacy notice that explains data processing, purposes, and rights under GDPR Art. 13(1) and the EU AI Act [ai_act_transparency · p.0].

**[P3.D6] Data Subject Rights**  
*Risk:* The app may not support data subject rights such as access, rectification, or erasure, which are required under GDPR Art. 15–18.  
*Mitigation:* Implement a data access workflow and ensure users can request data deletion or correction under GDPR Art. 17 [gdpr_2016_679 · p.18].

---

### **Low Severity Risks**

**[P1.D3] Data Portability**  
*Risk:* The app may not support data portability, which is required under GDPR Art. 20 for health data.  
*Mitigation:* Ensure users can export their data in a structured, commonly used format [gdpr_2016_679 · p.20].

**[P4.D2] Data Protection Officer (DPO) Appointment**  
*Risk:* The app may not have a DPO, which is required under GDPR Art. 37 for processing of health data.  
*Mitigation:* Appoint a DPO and ensure they are involved in DPIA and data protection compliance [gdpr_2016_679 · p.37].

---

### **Dimensions Not Covered**

- **[P5.D1] Human Oversight & Decision-Making** (AI Act)  
- **[P6.D2] Environmental & Social Impact**  
- **[P7.D1] Ethical Considerations & Fairness**  
- **[P7.D2] Non-Discrimination & Inclusion**  

---

This report highlights key risks and actionable mitigations to ensure compliance with GDPR, M

Now produce the JSON judgement object.